Investigating the effective concentration of jujube fruit in primary hypertensio
- Conditions
- Essential (primary) hypertension.Essential (primary) hypertension
- Registration Number
- IRCT20200506047325N2
- Lead Sponsor
- Gorgan University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 40
mmHg160 < blood pressure < mmHg 120 (Pre- and stage 1 hypertension)
Voluntary participation in this clinical study and written consent
Other heart diseases
Secondary hypertension
Serum potassium> 5.5 mmol / L or <3.5mmol / L
Doubling of serum creatinine in the last 6 months
Severe complications of diabetes or seriousmacrovascular events within 6 months (e.g., cerebral hemorrhage, cerebral infarction, or acute myocardial infarction)
Recent infection in the last 4 weeks
Primary or secondary kidney disease (e.g., IgA nephropathy, membranous nephropathy, or lupus nephritis)
Any cancer and malignancy
Severe mental disorder
Pregnant or lactating women or women who are planning to become pregnant or women who arenot using appropriate contraceptive methods
Participate in other clinical trials
Drug or jujube allergies
Use of other herbal medicines to control the symptoms of the present disease
History of smoking, drugs
Other conditions that the researchers considered in appropriate in this clinical study
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Hypertension. Timepoint: Round 0: starting the study and receiving medication (face-to-face consultation)Round 1: 2 weeks after receiving the drug (telephone)The third round: the fourth week, the end of the medical treatment period (face-to-face consultation). Method of measurement: Mercury barometer.
- Secondary Outcome Measures
Name Time Method Change in serum creatinine (SCr). Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood and urine tests.;EGFR. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood and urine tests.;Serum Albumin. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood and urine tests.;Lipid profiles. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood tests.;ECG. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Electrocardiograph.;Liver enzymes. Timepoint: At the beginning of the study and at the end of the drug treatment period (4th week). Method of measurement: Blood tests.